Stryker Corporation reported second quarter 2026 operating results, announcing net sales of $6.6 billion, a 9.4% increase from the prior year period. Organic net sales grew 9.0%, driven by unit volume increases across its MedSurg and Neurotechnology ($3.6 billion) and Orthopaedics ($3.0 billion) segments. Reported diluted earnings per share rose 44.1% to $3.30, while adjusted diluted EPS increased 17.9% to $3.69. The company narrowed its full-year 2026 guidance, now expecting organic net sales growth between 8.3% and 9.3%, with adjusted net earnings per diluted share in the range of $14.95 to $15.10. Stryker operates as a global leader in medical technologies, providing innovative products and services in MedSurg, Neurotechnology, and Orthopaedics.

Stryker Corporation announced a reorganization of its organizational structure, creating a new Ortho Tech business. This new unit combines the orthopaedic instruments portfolio from the Instruments business with the Mako and enabling technologies portfolio from the Other Orthopaedics business. The company will maintain two reportable segments: MedSurg and Neurotechnology and Orthopaedics. Consequently, Stryker is recasting its consolidated financial statements for the three years ended December 31, 2025, to align with this new segment reporting; however, these updates are not a restatement of previously issued financial statements. Stryker operates in the medical technology industry, providing medical equipment and surgical instruments.